secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001683168-24-005194
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals appoints Robert Infarinato as CFO effective August 1, 2024
-------------------------------------------------------------------------------

- Robert M. Infarinato appointed VP & CFO effective August 1, 2024; will serve as principal financial and accounting officer.
- Mr. Infarinato, 78, is an attorney and CPA with over 20 years of financial leadership in pharma and biotech.
- Base salary $180,000; eligible for annual bonus up to 30% of base based on performance goals.
- Caitlin Kontulis ceased as principal accounting officer on August 1 and will leave employment on August 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer